Dendrophenol
Based on 4 publication(s) in Google Scholar
Dendrophenol (Moscatilin) is a NF-κB inhibitor that inhibits inflammation. Dendrophenol exerts potent cytotoxic effect against tumor cells and induces cell cycle arrest and apoptosis. Dendrophenol has antitumor activity. In addition, Dendrophenol can inhibit vascular calcification by inhibiting the activation of WNT3/β-catenin.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.93%
- CAS No.: 108853-14-1
- Formule: C17H20O5
- Masse moléculaire:304.34
-
Stockage:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Dendrophenol
More
Activité biologique
|
NF-κB |
COX-2 |
HIF-1α |
Wnt3 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
2.1 μM
Compound: 23MST; MST
|
Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay
|
[PMID: 31047774] |
| A549 | IC50 |
5.73 μM
Compound: 9
|
Cytotoxicity against human A549 cells assessed as reduction in cell number
Cytotoxicity against human A549 cells assessed as reduction in cell number
|
[PMID: 25316316] |
| FaDu | IC50 |
2.55 μM
Compound: 1
|
Cytotoxicity against human FaDu cells assessed as cell viability incubated for 24 hrs by CCK-8 assay
Cytotoxicity against human FaDu cells assessed as cell viability incubated for 24 hrs by CCK-8 assay
|
[PMID: 32711292] |
| HCCLM3 | IC50 |
2.092 μM
Compound: 24
|
Antiproliferative activity against human HCCLM3 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
Antiproliferative activity against human HCCLM3 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
|
[PMID: 34931827] |
| HCT-116 | IC50 |
2.29 μM
Compound: 23MST; MST
|
Antiproliferative activity against human HCT116 cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells incubated for 72 hrs by MTT assay
|
[PMID: 31047774] |
| HepG2 | IC50 |
3.02 μM
Compound: 24
|
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
|
[PMID: 34931827] |
| HepG2 | IC50 |
3.76 μM
Compound: 23MST; MST
|
Antiproliferative activity against human HepG2 cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells incubated for 72 hrs by MTT assay
|
[PMID: 31047774] |
| HL-60 | IC50 |
0.082 μM
Compound: 1
|
Anti-cancer activity against human HL-60 cells
Anti-cancer activity against human HL-60 cells
|
[PMID: 32711292] |
| HL-60 | IC50 |
2.18 μM
Compound: 9
|
Cytotoxicity against human HL60 cells assessed as reduction in cell number
Cytotoxicity against human HL60 cells assessed as reduction in cell number
|
[PMID: 25316316] |
| MCF7 | IC50 |
6.2 μM
Compound: 9
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell number
Cytotoxicity against human MCF7 cells assessed as reduction in cell number
|
[PMID: 25316316] |
| MDA-MB-231 | IC50 |
0.082 μM
Compound: 23MST; MST
|
Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay
|
[PMID: 31047774] |
| MKN-45 | IC50 |
3.51 μM
Compound: 23MST; MST
|
Antiproliferative activity against human MKN45 cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human MKN45 cells incubated for 72 hrs by MTT assay
|
[PMID: 31047774] |
| N2a | IC50 |
>20 μM
Compound: Mos
|
Cytotoxicity against mouse Neuro2a cells assessed as reduction in cell viability after 12 hrs by MTT assay
Cytotoxicity against mouse Neuro2a cells assessed as reduction in cell viability after 12 hrs by MTT assay
|
[PMID: 31291099] |
| N2a | IC50 |
>20 μM
Compound: Mos
|
Cytotoxicity against mouse Neuro2a cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against mouse Neuro2a cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 31291099] |
| NCI-H23 | IC50 |
33.41 μM
Compound: 1
|
Anti-cancer activity against human NCI-H23 cells
Anti-cancer activity against human NCI-H23 cells
|
[PMID: 32711292] |
| Platelet | IC50 |
61.8 μM
Compound: 1
|
Antiplatelet activity against washed rabbit platelet assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 3 mins by turbidimetric method
Antiplatelet activity against washed rabbit platelet assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 3 mins by turbidimetric method
|
[PMID: 7798962] |
| RAW | IC50 |
36.8 μM
Compound: 8
|
Inhibition of LPS and TNF-alpha-activated NO production in murine RAW 264.7 cells
Inhibition of LPS and TNF-alpha-activated NO production in murine RAW 264.7 cells
|
[PMID: 17253844] |
| RAW264.7 | IC50 |
27.6 μM
Compound: 8
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production
|
[PMID: 20483604] |
| RAW264.7 | IC50 |
4.4 μM
Compound: 1
|
Cytotoxicity against mouse RAW264.7 cells assessed as decrease in cell proliferation rate after 24 hrs by MTS assay
Cytotoxicity against mouse RAW264.7 cells assessed as decrease in cell proliferation rate after 24 hrs by MTS assay
|
[PMID: 27777005] |
| SH-SY5Y | IC50 |
>20 μM
Compound: Mos
|
Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability after 12 hrs by MTT assay
Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability after 12 hrs by MTT assay
|
[PMID: 31291099] |
| SH-SY5Y | IC50 |
>20 μM
Compound: Mos
|
Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 31291099] |
| SMMC-7721 | IC50 |
4.07 μM
Compound: 9
|
Cytotoxicity against human SMMC7721 cells assessed as reduction in cell number
Cytotoxicity against human SMMC7721 cells assessed as reduction in cell number
|
[PMID: 25316316] |
| SW480 | IC50 |
6.88 μM
Compound: 9
|
Cytotoxicity against human SW480 cells assessed as reduction in cell number
Cytotoxicity against human SW480 cells assessed as reduction in cell number
|
[PMID: 25316316] |
| THP-1 | IC50 |
226.09 μM
Compound: 1
|
Anti-cancer activity against human THP-1 cells
Anti-cancer activity against human THP-1 cells
|
[PMID: 32711292] |
Dendrophenol (5-100 μM; 1 h) inhibits the expression of COX-2, iNOS, HIF-1α and NF-κB and inhibits cell activation in LPS (HY-D1056) treated macrophages[1].
Dendrophenol (0-50 μM; 15 h-6 days) exerts potent cytotoxic effect against tumor cell lines from placenta, lung and stomach, and can cause cell G2 phase arrest[2].
Dendrophenol (1 μM; 4 days) reduces calcium deposition via the WNT3/β-catenin pathway and reduces calcification induced inflammation by IL13RA2 and STAT3 in Phosphate-treated human aortic smooth muscle cells[3].
Dendrophenol (3-30 μM; 24 h) induces apoptosis of human colon cancer cell HCT-116 by tubulin depolymerization, DNA damage stress and JNK signaling pathway[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:LPS (HY-D1056) treated RAW264.7 cells
-
Concentration:10, 30, 50 and 100 μM
-
Incubation Time:1 h
-
Result:Inhibited the levels of COX-2 and iNOS in a concentration‐dependent manner.
-
Cell Line:Phosphate treated HASMCs
-
Concentration:1 μM
-
Incubation Time:4 days
-
Result:Reduced the levels of WNT3 and β-catenin.
Increased the level of IL13RA2.
Reduced the levels of p-STAT3, IL-1β and IL-6.
-
Cell Line:HCT-116 cells
-
Concentration:3, 10 and 30 μM
-
Incubation Time:24 h
-
Result:Increased the phosphorylation level of JNK1/2.
Dendrophenol (50-100 mg/kg; intraperitoneal injection; 5 times a week for 2 weeks) has antitumor effect in mouse tumor model[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nicotine and Vitamin D3 (HY-15398) treated male C57BL/6J mice aged 25 weeks old[3]
-
Dosage:10 mg/kg
-
Administration:Intraperitoneal injection (i.p.); 3 weeks
-
Result:Reduced calcium accumulation in the thoracic aorta and aortic valves of the mice.
Reduced the expression of calcification-related genes, such as ALPL, BMP2 and RUNX2.
-
Animal Model:HCT-116 cells treated male severe combined immunodeficient mice[4]
-
Dosage:50 and 100 mg/kg
-
Administration:Intraperitoneal injection (i.p.); five times a week for two weeks
-
Result:Significantly inhibited tumor growth and did not result in weight loss.
Chemical Information
-
CAS No. 108853-14-1
-
Appearance Solid
-
Masse moléculaire 304.34
-
Formule C17H20O5
-
Color White to off-white
-
SMILES
COC1=C(C=CC(CCC2=CC(OC)=C(C(OC)=C2)O)=C1)O
-
Synonyms
Moscatilin
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
-
Int Immunopharmacol
Moscatilin alleviates severe acute pancreatitis by activating the NRF2/HO-1 pathway to inhibit ferroptosis. [Abstract]2026 Jan 15:169:115972. PMID: 41352097 -
Chem Biol Drug Des
Moscatilin Induces Ferroptosis in Clear Cell Renal Cell Carcinoma via the JAK-STAT Signaling Pathway. [Abstract]2025 Mar;105(3):e70071. PMID: 40070232 -
Immunopharmacol Immunotoxicol
2025 Dec;47(6):872-879. PMID: 41243602
Solvant et solubilité
DMSO : 100 mg/mL (328.58 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.21 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.21 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (280 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Liu YN, et al. Moscatilin repressed lipopolysaccharide-induced HIF-1alpha accumulation and NF-kappaB activation in murine RAW264.7 cells. Shock. 2010 Jan;33(1):70-5. [Content Brief]
[2]. Ho CK, et al. Moscatilin from the orchid Dendrobrium loddigesii is a potential anticancer agent. Cancer Invest. 2003;21(5):729-36. [Content Brief]
[3]. Zhang T, et al. Moscatilin inhibits vascular calcification by activating IL13RA2-dependent inhibition of STAT3 and attenuating the WNT3/β-catenin signalling pathway. J Adv Res. 2024 Mar 2:S2090-1232(24)00082-1. [Content Brief]
[4]. Chen TH, et al. Moscatilin induces apoptosis in human colorectal cancer cells: a crucial role of c-Jun NH2-terminal protein kinase activation caused by tubulin depolymerization and DNA damage. Clin Cancer Res. 2008 Jul 1;14(13):4250-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2858 mL | 16.4290 mL | 32.8580 mL | 82.1450 mL |
| 5 mM | 0.6572 mL | 3.2858 mL | 6.5716 mL | 16.4290 mL | |
| 10 mM | 0.3286 mL | 1.6429 mL | 3.2858 mL | 8.2145 mL | |
| 15 mM | 0.2191 mL | 1.0953 mL | 2.1905 mL | 5.4763 mL | |
| 20 mM | 0.1643 mL | 0.8214 mL | 1.6429 mL | 4.1072 mL | |
| 25 mM | 0.1314 mL | 0.6572 mL | 1.3143 mL | 3.2858 mL | |
| 30 mM | 0.1095 mL | 0.5476 mL | 1.0953 mL | 2.7382 mL | |
| 40 mM | 0.0821 mL | 0.4107 mL | 0.8214 mL | 2.0536 mL | |
| 50 mM | 0.0657 mL | 0.3286 mL | 0.6572 mL | 1.6429 mL | |
| 60 mM | 0.0548 mL | 0.2738 mL | 0.5476 mL | 1.3691 mL | |
| 80 mM | 0.0411 mL | 0.2054 mL | 0.4107 mL | 1.0268 mL | |
| 100 mM | 0.0329 mL | 0.1643 mL | 0.3286 mL | 0.8214 mL |
Dendrophenol Related Classifications
HY-N6031 Related Classifications
Powered by Bioz